Targeting IL-1 controls refractory pityriasis rubra pilaris
Science Advances · 2024
DOI: 10.1126/sciadv.ado2365 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Eloi Schmauch und 22 weiteren Autor:innen. Beteiligte Einrichtung: Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA. Hauptthemen laut MEDLINE: Pityriasis Rubra Pilaris, Interleukin-1beta, Interleukin 1 Receptor Antagonist Protein, Keratinocytes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis, atopic dermatitis, healed PRP, and healthy controls, we identified IL-1β as a key mediator, orchestrating an NF-κB–mediated IL-1β–CCL20 axis, including activation of CARD14 and NOD2. Treatment of three patients with the IL-1 antagonists anakinra and canakinumab resulted in rapid clinical improvement and reversal of the PRP-associated molecular signature with a 50% improvement in skin lesions after 2 to 3 weeks. This transcriptional signature was consistent with in vitro stimulation of keratinocytes with IL-1β. With the central role of IL-1β underscoring its potential as a therapeutic target, our findings propose a redefinition of PRP as an autoinflammatory keratinization disorder. Further clinical trials are needed to validate the efficacy of IL-1β antagonists in PRP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
- Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, 8049 Zurich, Switzerland.
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA.
- Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA.
ORCID-Profile: Eloi Schmauch, Yannik Severin, Xianying Xing, Aaron Mangold, Curdin Conrad, Pål Johansen, J Michelle Kahlenberg, Mark Mellett, Alexander Navarini, Stefan Nobbe, Mrinal K Sarkar, Abhigyan Satyam, Lam C Tsoi, Lars E French, Jakob Nilsson, Suvi Linna-Kuosmanen, Minna U Kaikkonen, Berend Snijder, Manolis Kellis, Johann E Gudjonsson, George C Tsokos, Emmanuel Contassot, Antonios G A Kolios
Zitieren
APA
Schmauch, E., Severin, Y., Xing, X., Mangold, A., Conrad, C., Johansen, P., Kahlenberg, J. M., Mellett, M., Navarini, A., Nobbe, S., Sarkar, M. K., Satyam, A., Tsoi, L. C., French, L. E., Nilsson, J., Linna-Kuosmanen, S., Kaikkonen, M. U., Snijder, B., Kellis, M., …, & Kolios, A. G. A. (2024). Targeting IL-1 controls refractory pityriasis rubra pilaris. Science Advances. https://doi.org/10.1126/sciadv.ado2365
Vancouver
Schmauch E, Severin Y, Xing X, Mangold A, Conrad C, Johansen P, et al. Targeting IL-1 controls refractory pityriasis rubra pilaris. Science Advances. 2024. doi:10.1126/sciadv.ado2365
BibTeX
@article{Schmauch2024,
author = {Schmauch, Eloi and Severin, Yannik and Xing, Xianying and Mangold, Aaron and Conrad, Curdin and Johansen, Pål and Kahlenberg, J Michelle and Mellett, Mark and Navarini, Alexander and Nobbe, Stefan and Sarkar, Mrinal K and Satyam, Abhigyan and Tsoi, Lam C and French, Lars E and Nilsson, Jakob and Linna-Kuosmanen, Suvi and Kaikkonen, Minna U and Snijder, Berend and Kellis, Manolis and Gudjonsson, Johann E and Tsokos, George C and Contassot, Emmanuel and Kolios, Antonios G A},
title = {Targeting IL-1 controls refractory pityriasis rubra pilaris},
journal = {Science Advances},
year = {2024},
doi = {10.1126/sciadv.ado2365}
}
EUVIMED